Calyx Secures $100K in

Calyx has secured $100,000 in investment capital from investors. This funding announcement comes as Calyx, alongside Invicro, has recently unified its operations under the new brand, Perceptive.

The combined entity, Perceptive, builds upon a collective 50-year history, providing specialized support to global pharmaceutical, biotech, and clinical research organizations.

Perceptive’s comprehensive offerings span the entire research and development lifecycle, from discovery and preclinical stages through clinical development to post-marketing activities.

The company delivers best-in-class services, including advanced imaging biomarkers and core lab services.

Additionally, Perceptive offers innovative technologies in areas such as randomization and trial supply management (RTSM), sophisticated analytics, and specialized software solutions.

This strategic investment of $100,000 will enable Perceptive to further enhance its capabilities and expand its service delivery across its diverse portfolio.

The capital is earmarked for growth initiatives aimed at strengthening the company's market position and continuing to provide cutting-edge solutions to its global clientele.

This funding round underscores investor confidence in Perceptive's integrated approach and its potential to drive innovation and efficiency within the life sciences sector, supporting the critical work of pharmaceutical and biotech companies.

With this new capital, Perceptive plans to accelerate the development and deployment of its integrated platforms, ensuring it remains at the forefront of supporting critical R&D processes from discovery to commercialization.

The company is focused on expanding its operational reach and deepening its impact within the industry, ultimately aiming to solidify its role as a pivotal partner for organizations navigating the complexities of drug discovery and development in an evolving global landscape.